Select Language
CD27 Ligand
CD27 Ligand Overview
| English Name | CD70 antigen | Approved Drugs | 0 |
| Drugs in Clinical Trials | 31 | Target Synonym | CD70 antigen，Surface Antigen CD70，LPFS3，CD27L，Tumor necrosis factor ligand superfamily member 7，CD27LG，CD27-L，CD70，CD70 Molecule，TNFSF7，Tumor Necrosis Factor (Ligand) Superfamily， Member 7，Tumor Necrosis Factor Ligand 8A，Ki-24 Antigen，TNLG8A，CD27 Ligand |
| Highest Development Stage | Phase 2 Clinical | ||
| English Name | CD70 antigen |
| Target Synonym | CD70 antigen，Surface Antigen CD70，LPFS3，CD27L，Tumor necrosis factor ligand superfamily member 7，CD27LG，CD27-L，CD70，CD70 Molecule，TNFSF7，Tumor Necrosis Factor (Ligand) Superfamily， Member 7，Tumor Necrosis Factor Ligand 8A，Ki-24 Antigen，TNLG8A，CD27 Ligand |
| Approved Drugs | 0 |
| Drugs in Clinical Trials | 31 |
| Highest Development Stage | Phase 2 Clinical |
CD27 Ligand Product List
- Product Category
Protein (14)
- Product Status
Launched (15)
- Species
Mouse (3)Human (11)
- Tag
Mouse IgG Fc Tag (2)His Tag (6)His Tag & Avi Tag (1)Fc Tag (1)His Tag & Flag Tag (2)His Tag & Avi Tag & Flag Tag (1)Llama IgG Fc Tag (1)
- Conjugate
Unconjugated (6)Biotin-labeled (2)FITC Labeled (2)APC Labeled (1)PE Labeled (1)AF647 Labeled (1)AF488 Labeled (1)
Add to Cart
Total: 14
- 1
- 2
CD27 Ligand Synonyms
CD70,CD27LG,TNFSF7,TNFSF7G,CD27L
Antibody Project Trading Platform
| Project Name | Project Stage | Molecule Type | Molecule Source | Disease Area | Indication |
|---|---|---|---|---|---|
| CD70 VHH - 01 | Lead | Monoclonal | Nanobody | Hematological Malignancy | Non-hodgkin lymphoma |
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Cusatuzumab | ARGX-110; JNJ-4550 | Phase 2 Clinical | Argenx Se | Myelodysplastic Syndromes; Neoplasms; Leukemia, Myelomonocytic, Chronic; Leukemia, Myeloid, Acute | Details |
| PRO-1160 | PRO-1160 | Phase 2 Clinical | ProfoundBio (Suzhou) Co Ltd | Solid tumours; Carcinoma, Renal Cell; Nasopharyngeal Carcinoma; Lymphoma; Lymphoma, Non-Hodgkin | Details |
| ADI-270 | ADI-270 | Phase 2 Clinical | Adicet Bio Inc | Carcinoma, Renal Cell | Details |
| CD70 Targeted CAR-T Cells Therapy(UTC Therapeutics) | Phase 2 Clinical | UTC Therapeutics Inc | Solid tumours; Urologic Neoplasms; Lymphoma | Details | |
| Cord Blood-derived CAR NK Cells Targeting CD19/CD70(Shanghai Tongji Hospital) | Phase 2 Clinical | Shanghai Tongji Hospital | Lymphoma, B-Cell | Details | |
| MP0533 | MP0533 | Phase 2 Clinical | Molecular Partners Ag | Leukemia, Myeloid, Acute | Details |
| CTX-131 | CTX-131 | Phase 2 Clinical | Crispr Therapeutics Ag | Lymphoma, B-Cell; Carcinoma, Renal Cell; Esophageal Neoplasms; Pancreatic Neoplasms; Neoplasms; Mesothelioma; Leukemia, Myeloid, Acute; Lymphoma, T-Cell; Uterine Cervical Neoplasms | Details |
| GD2/CD70 Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) | bi-4SCAR GD2/CD70 | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Neoplasms | Details |
| CD19/70 Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Lymphoma, B-Cell; Leukemia, B-Cell | Details | |
| PSMA/CD70 Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) | bi-4SCAR PSMA/CD70 | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Neoplasms | Details |
| SEA-CD70 | SEA-CD70; PF-08046040 | Phase 1 Clinical | Seagen Inc | Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
| anti-CD70 CAR T-cell therapy linked with modified IL-8 receptor (University of Florida) | Phase 1 Clinical | University Of Florida | Ovarian Neoplasms; Glioblastoma; Pancreatic Neoplasms | Details | |
| BR-108 | BR-108 | Phase 1 Clinical | BioRay Pharmaceutical Co Ltd | Hematologic Neoplasms; Leukemia | Details |
| ARX-305 | ARX-305; NCB-002 | Phase 1 Clinical | Ambrx Inc | Neoplasms | Details |
| CD70-CAR-NK Cell Therapy(Second Affiliated Hospital School Of Zhejiang University School Of Medicine) | Phase 1 Clinical | Second Affiliated Hospital School Of Zhejiang University School Of Medicine | Leukemia, Myeloid, Acute; Lymphoma, T-Cell | Details | |
| Anti-CD70-CAR-T Cell therapy(First Song Biotechnology) | Phase 1 Clinical | Shanghai First Song Therapeutics Co Ltd | Carcinoma, Renal Cell | Details | |
| IB-T101 | Phase 1 Clinical | Inceptor Bio LLC | Carcinoma, Renal Cell | Details | |
| Anti-BCMA/CD70 CAR-T cells therapy(The Children'S Hospital, Zhejiang University School Of Medicine) | Phase 1 Clinical | The Children'S Hospital, Zhejiang University School Of Medicine | Nephrosis | Details | |
| CD70 UCAR T cells Therapy (Nanjing Calmhome Cell and Gene Engineering Institute) | CHT-101; CHT101 | Phase 1 Clinical | Nanjing Calmhome Cell and Gene Engineering Institute Co Ltd | Ovarian Neoplasms; Solid tumours; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Nasopharyngeal Carcinoma; Glioma; Uterine Cervical Neoplasms; Neoplasm Metastasis | Details |
| Chimeric Antigen Recertor Treatment Targeting CD70(Baylor College of Medicine) | Phase 1 Clinical | Baylor College Of Medicine | Leukemia, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Leukemia, T-Cell | Details | |
| CAR T-cell Therapy Directed to CD70(St Jude Children's Research Hospital) | Phase 1 Clinical | St. Jude Children'S Research Hospital | Hematologic Neoplasms; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute; Lymphoma | Details | |
| CD70-targeted CAR-NKT Cells Therapy (CureGenetics) | CGC729; CGC-729 | Phase 1 Clinical | Suzhou Cure Genetics Biosciences Co Ltd | Solid tumours; Carcinoma, Renal Cell | Details |
| CD70-CART（Hrain） | HR010; HR-010 | Phase 1 Clinical | Hrain Biotechnology Co Ltd | Carcinoma, Renal Cell | Details |
| Anti-CD19/CD70 NK cell therapy (Zhejiang University) | Phase 1 Clinical | Zhejiang University | Lymphoma, B-Cell | Details | |
| CD70 CAR-T cell therapy (Chongqing Precision Biotech) | Phase 1 Clinical | Chongqing Precision Biotechnology Co Ltd | Ovarian Neoplasms; Solid tumours; Carcinoma, Renal Cell; Neoplasms; Genital Neoplasms, Female; Neoplasm Metastasis; Uterine Cervical Neoplasms | Details | |
| IMM-40H | IMM-40H; IMM40H | Phase 1 Clinical | ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd | Hematologic Neoplasms; Solid tumours; Neoplasms | Details |
| ALLO-316 | ALLO-316 | Phase 1 Clinical | Cellectis Sa, Overland Pharmaceuticals (Shanghai) Co Ltd | Carcinoma, Renal Cell; Leukemia, Myeloid, Acute | Details |
| CD70 CAR T-cell therapy (Yake Biotechnology) | Phase 1 Clinical | Zhejiang University | Multiple Myeloma; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin | Details | |
| C-4-29 | Phase 1 Clinical | Chongqing Precision Biotechnology Co Ltd | Carcinoma, Renal Cell; Multiple Myeloma | Details | |
| CGC-738 | CGC-738; CGC738 | Clinical | Suzhou Cure Genetics Biosciences Co Ltd | Carcinoma, Renal Cell | Details |
| CD19/CD70 CAR-NK cells therapy (Rongu Biotechnology) | RG-1970 | Clinical | Hangzhou Rongu Biotechnology Co Ltd | Lymphoma, B-Cell; Neoplasms | Details |
- Overview
- Product List
- Clinical Drug Information
Share to:
Online Message
[North America]: 1 Innovation Way, Newark, DE 19711, USA [Switzerland]: Switzerland Innovation Park Basel Area, Novartis Campus, Lichtstrasse 35, 4056 Basel
Email：order@acrobiosystems.com
Copyright © 2025 ACROBiosystems. All Rights Reserved
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland